>
Organization
Novartis AG
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed

News on Novartis AG

... our information technology systems, and other risks and factors referred to in Novartis AG's current Form 2F on file with the US Securities and Exchange ...
... our information technology systems, and other risks and factors referred to in Novartis AG's current Form 2F on file with the US Securities and Exchange ...
... Amgen, Merck & Co., Inc., Hoffmann-La Roche AG., Teva Pharmaceuticals Industries Limited, Novartis AG, CELGENE CORPORATION, Sanofi S.A., JOHNSON & JOHNSON, AMAG Pharmaceuticals and Shire ...
... Dr. Jill Biden, Dr. Sanjay Gupta, Kaiser Permanente CEO Bernard Tyson and Novartis Chief Digital Officer Bertrand Bodson, the StartUp Health Festival will bring together ...
... presents an assessment of the competitive landscape, dominated by key companies including Novartis AG, Pfizer Inc, GlaxoSmithKline Plc, Celgene Corp., Mylan N.V., Merck & Co., ...
... placebo-controlled Phase 2b clinical trials being conducted by Conatus in collaboration with Novartis, the EmricasaN, a Caspase inhibitOR, for Evaluation (ENCORE) trials, designed to evaluate ...
... Basel - Novartis, a leader in immuno-dermatology, announced today the initiation of Phase III trials ...
... our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange ...
... please visit https://clinicaltrials.gov/show/NCT02953678 . The REACH clinical program also includes the collaborative Novartis-sponsored randomized pivotal Phase 3 studies in acute GVHD (REACH2) and chronic GVHD ...
... our information technology systems, and other risks and factors referred to in Novartis AG's current Form 2F on file with the US Securities and Exchange ...
Subscribe now for full coverage on Novartis AG
Start My Free Trial